TipRanks
Go Ultimate55% OFF

HYUGA PRIMARY CARE Co.,Ltd. (7133) AI Stock Analysis

0 Followers
JP:7133

HYUGA PRIMARY CARE Co.,Ltd.

(TSE/TYO:7133)

Select Model
Rating:72Outperform
Price Target:JPY 1,822.00â–¼(-13.49% Downside)
Action:reiterated
Date:09/29/26

The overall score reflects strong technical momentum and a fair valuation, balanced against mixed financial health. While revenue scaling is excellent, tightening profit margins and reduced cash flow flexibility present near-term operational challenges.

Positive Factors
Consistent Revenue GrowthSustained revenue expansion indicates continued demand for the company’s pharmacy and primary-care support services. Growth at this pace can broaden the operating base, improve scale economics, and provide resources to reinvest in patient support and service capacity over the next several quarters.
Negative Factors
Margin CompressionThe sharp decline in gross and net margins shows that higher sales are not currently translating into proportional profit growth. If cost pressure or unfavorable mix persists, earnings quality could remain weaker and reduce the funds available for expansion, service investment, or balance-sheet improvement.

HYUGA PRIMARY CARE Co.,Ltd. (7133) vs. iShares MSCI Japan ETF (EWJ)

-40%-20%0%20%40%60%80%JP:7133+71.38%EWJ+10.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 15.03B
Dividend Yield
0.95%
Average Volume (3M)
29.95K
Price to Earnings (P/E)
24.4
Beta (1Y)
0.12
Revenue Growth
22.80%
EPS Growth
-10.77%
Country
Japan
Employees
882
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

HYUGA PRIMARY CARE Co.,Ltd. Business Overview & Revenue Model

Company Description

HYUGA PRIMARY CARE Co.,Ltd., established in 2007 and based in Kasuga, Japan, specializes in delivering a variety of primary care services, encompassing home-visit pharmacies, nursing support, and personalized care planning. The company extends its ex...

How the Company Makes Money

The company primarily generates revenue through dispensing-pharmacy operations, where it earns fees associated with filling prescriptions issued by medical institutions and receives payment for providing medication guidance and related pharmacy servi...

HYUGA PRIMARY CARE Co.,Ltd. Financial Statement Overview

Summary

Impressive top-line growth and solid return on equity are offset by compressing profit margins, rising debt levels, and a sharp decline in free cash flow generation.

Income Statement

75Positive

Balance Sheet

68Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue12.68B11.98B9.98B8.29B6.66B5.78B
Gross Profit2.38B2.25B2.41B1.88B1.56B1.24B
EBITDA1.37B1.18B1.31B854.38M627.27M568.69M
Net Income614.95M501.88M719.03M441.03M382.88M328.45M
Balance Sheet
Total Assets8.67B8.29B7.05B6.35B2.92B2.54B
Cash, Cash Equivalents and Short-Term Investments1.24B1.02B565.93M688.01M567.69M719.56M
Total Debt2.86B3.22B2.65B2.80B251.54M330.21M
Total Liabilities5.90B5.56B4.68B4.71B1.44B1.46B
Stockholders Equity2.77B2.73B2.37B1.64B1.48B1.07B
Cash Flow
Free Cash Flow035.71M485.51M473.20M102.59M228.92M
Operating Cash Flow0492.94M771.32M706.64M342.25M484.60M
Investing Cash Flow0-319.13M-473.98M-1.13B-383.39M-320.25M
Financing Cash Flow0281.88M-419.43M538.78M-110.73M16.93M

HYUGA PRIMARY CARE Co.,Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price2106.00

Price Trends

50DMA1715.20Positive
100DMA1436.75Positive
200DMA1257.84Positive

Market Momentum

MACD102.63Positive
RSI95.10Negative
STOCH50.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7133, the sentiment is Positive. The current price of 2106.00 is above the 20-day moving average (MA) of 2105.55, above the 50-day MA of 1715.20, and above the 200-day MA of 1257.84, indicating a bullish trend. The MACD of 102.63 indicates Positive momentum. The RSI at 95.10 is Negative, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7133.

HYUGA PRIMARY CARE Co.,Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:7133 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7133JP:713372OutperformJPY 15.34B24.42―0.95%22.80%-10.77%
JP:7071JP:707164NeutralJPY 37.65B11.89―1.10%6.17%-33.01%
JP:2373JP:237361NeutralJPY 5.14B18.16―4.43%4.76%-52.55%
JP:2425JP:242556NeutralJPY 2.49B29.36―3.37%-5.72%-73.78%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:7061JP:706152NeutralJPY 3.83B11.24――14.91%-39.00%

* General Sector Average

Performance Comparison

-50%0%50%JP:7133JP:2373JP:2425JP:7061JP:7071Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7133 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:7133HYUGA PRIMARY CARE Co.,Ltd.2106.00889.9173.18%
JP:2373Care Twentyone Corporation384.00-46.18-10.74%
JP:2425Care Service Co., Ltd.653.00-103.28-13.66%
JP:7061Japan Hospice Holdings Inc.430.00-851.94-66.46%
JP:7071Amvis Holdings.Inc.364.00-58.69-13.88%

HYUGA PRIMARY CARE Co.,Ltd. Corporate Events

HYUGA PRIMARY CARE Unveils Q1 FY2027 Results and Outlook

Aug 27, 2026

HYUGA PRIMARY CARE Co., Ltd. released its financial results for the first quarter of the fiscal year ending March 2027, outlining performance and trends under its TSE Growth Market listing. The disclosure highlights how the quarter’s results fi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026